Clinical Trial Update: Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating chemotherapy with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Squamous Cell Head and Neck Carcinoma, Recurrent or Metastatic Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-04-07